2011

Has It Been Found? What Does It Reveal About Pfizer's Social Media Implementation Plan?. Ray Kerins (@raykerins), Vice President of Worldwide Communications at Pfizer, talks about Pfizer's 'groundbreaking internal Social Media Playbook' but won't show it to us. What can be in the playbook? How many people does Pfizer dedicate to social media? This article discusses those questions and offers a peek into a playbook contender.

Welcome to Volume 10, Issue #2 (JANUARY 19, 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #16 (27 OCTOBER 2011) of Pharma Marketing News.

This is the last in a series of three articles highlighting points made by Kantar Health executives in a recent webinar titled, 'Getting It Right in the Emerging Markets: Identifying the opportunities and avoiding the pitfalls in conducting market research in new geographies.'

A Search Ad Format That Has All FDA Could Want... But Pharma Can't Use It! Data suggest that Google's OneBox NIH Rx ads effectively reduce organic search visitation driven to pharma sites pushing the traffic to NIH content instead. Is it logical to conclude that Google stands to gain paid ad revenue when pharma marketers have to compete with OneBox ads by buying more paid search placements to make up for the loss of organic search visits?

This just in: FDA Won't Issue Specific Guidance for Youtube, Facebook, or Twitter. Claims These Media Are Just Passing Fads! Now Back to Your Regularly-Scheduled TV Ad.

Allergan, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, Novo, and Sanofi-Aventis filed a 'citizen petition' with the FDA, urging the agency to 'establish comprehensive, clear and binding regulations to guide the industry' in communicating off-label drug information to physicians and payers. Although the words 'Internet' and 'Social Media' are not mentioned in the petition, it is likely to hold up social media guidelines regarding 'unsolicited requests' that were promised as the first in a series of FDA guidelines.

If you're thinking of developing a mobile application (app) for patients or physicians, you need to consider the myriad platforms -- hardware plus software combinations -- that are out there and determine which platform is best suited for your intended audience. Your choice of platform will impact your app's performance, maintenance, and security, which in turn will make or break the success of the app.

Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.